Amarin (AMRN -7.8%) comes under pressure after the FDA's update to its Orange Book gives it's...

|About: Amarin Corporation PLC (AMRN)|By:, SA News Editor

Amarin (AMRN -7.8%) comes under pressure after the FDA's update to its Orange Book gives it's fish oil pill Vascepa "no unexpired exclusivity," though no NCE decision was made.